The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.
Predicting oncologic outcomes is important for patient counseling, clinical trial design, and biomarker study testing. Mayo Clinic researchers conducted a study to develop prognostic models for progression-free and cancer-specific survival in patients with clear cell renal cell carcinoma (ccRCC), papillary RCC (papRCC), and chromophobe RCC (chrRCC). Using a large institutional experience, researchers generated specific prognostic models for oncologic outcomes in ccRCC, papRCC, and chrRCC that rely on features previously shown-and validated-to be associated with survival. These updated models should inform patient prognosis, biomarker design, and clinical trial enrollment. The study was published in European Urology.